Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).
about
The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology.Characterization of Oropharyngeal Carriage Isolates of Neisseria meningitidis in Healthy Korean Adolescents in 2015.Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010.The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater Sao Paulo, Brazil.Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003.Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type duriClonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A).The changing epidemiology of meningococcal disease in North America 1945-2010.The epidemiology of meningococcal disease and the impact of vaccines.MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Controlling serogroup B invasive meningococcal disease: the Canadian perspective.Evolving meningococcal immunization strategies.Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States.Invasive meningococcal disease caused by Neisseria meningitidis strains expressing both serogroup Y and W-135 antigenic specificities.Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology.Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135.Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.
P2860
Q33610843-7ADE0711-3CC6-4538-BFE8-E412ACBF23B4Q33770335-B17F7348-73D8-4972-AF0B-5C8D22626D13Q34396428-AF15370B-4F59-46C1-A4B7-46D441361FDBQ34500581-733668BA-E70D-428A-84F0-CC5E96750162Q34746633-355A0E95-504A-444D-BFCC-25AC07F90E60Q35328649-88915D26-DF4E-4E2E-83D2-86948AC6FB64Q35708801-8885C10D-8BC4-452F-8454-593D78568147Q35784362-8F8069E3-2DAD-4E37-A8A6-27A87413D7ADQ35942903-170E7E98-C702-4714-8565-6C6EBA3CBC6EQ36333592-289FB07C-34A6-438B-845C-0B41BB29A68FQ36363154-DF29CB84-74CC-4888-80B9-5482DD4D1E4DQ36407498-D8C4B230-E9C7-493C-9DF7-7AADB135D625Q36887966-EE974E7F-049F-4E4C-9CE6-C02A67519212Q37706585-FF3E0297-A3A7-4B8B-B416-0FEC91EE2477Q38028992-58E2ACE6-BD7E-4116-BD1F-A63FD9BC277FQ38105338-B446E697-F38F-4187-B7DC-449481D71688Q38286082-8D53EE44-0767-4484-AA06-A08164250977Q38325374-9743F144-2B55-4B1B-B294-A6D058333DA5Q38957806-7A52DA59-0646-4505-94EA-2F46BFDEAC3FQ42266218-C67B40EB-58BC-4404-9B87-E2BC90ABFD4EQ42569935-83F0B76B-A730-4648-871F-1F2B133530AEQ44495758-C30D6860-A68F-45C9-A727-6D924D2EAF0CQ46519245-50BC794C-527D-472C-BD43-28B0E66E5D0AQ55191650-15333026-9122-4AEB-9BA3-943FB085C50D
P2860
Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@ast
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@en
type
label
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@ast
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@en
prefLabel
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@ast
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@en
P2093
P2860
P356
P1476
Invasive meningococcal disease ...... pe antigen P1.19 (B:17:P1.19).
@en
P2093
Averil M Henderson
Dennis K S Law
Jan Stoltz
Louise Ringuette
Manon Lorange
Michel Giguère
Philippe De Wals
Raymond S W Tsang
Réjean Dion
Wendell D Zollinger
P2860
P304
P356
10.1128/JCM.00601-06
P407
P577
2006-08-01T00:00:00Z